Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
BioGaia AB's Sloan Ratio for the quarter that ended in Mar. 2026 was -0.31%.
As of Mar. 2026, BioGaia AB has a Sloan Ratio of -0.31%, indicating the company is in the safe zone and there is no funny business with accruals.
BioGaia AB (OTCPK:BGLAF) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, BioGaia AB has a Sloan Ratio of -0.31%, indicating the company is in the safe zone and there is no funny business with accruals.
BioGaia AB Sloan Ratio % Related Terms
BioGaia AB Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Sloan Ratio % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
BioGaia AB's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
BioGaia AB's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was 9.207 (Jun. 2025 ) + 7.029 (Sep. 2025 ) + 10.629 (Dec. 2025 ) + 8.523 (Mar. 2026 ) = $35.4 Mil.
BioGaia AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was 8.082 (Jun. 2025 ) + 11.752 (Sep. 2025 ) + 8.987 (Dec. 2025 ) + 7.552 (Mar. 2026 ) = $36.4 Mil.
BioGaia AB's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was -0.122 (Jun. 2025 ) + -0.109 (Sep. 2025 ) + -0.049 (Dec. 2025 ) + -0.136 (Mar. 2026 ) = $-0.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a Sloan Ratio % of -0.31% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on BioGaia AB and its competitors.
Is BioGaia AB's Sloan Ratio % too high?
BioGaia AB's current Sloan Ratio % is -0.31%. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Sloan Ratio % compare to ZTS and UTHR?
BioGaia AB's Sloan Ratio % of -0.31% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Drug Manufacturers company?
A good Sloan Ratio % depends on the Drug Manufacturers industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on BioGaia AB and its competitors. BioGaia AB's current Sloan Ratio % is -0.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $13.38, compared to a current price of $12.20 — trading 8.8% below its estimated fair value. The current Sloan Ratio % is -0.31%. BioGaia AB's overall GF Score™ is 100/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Sloan Ratio % is -0.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 8.8% below its estimated GF Value™ of $13.38.
GuruFocus considers BioGaia AB to be Fairly Valued.
Key valuation signals for BGLAF:
Sloan Ratio %: -0.31%
GF Value™: $13.38 vs. price of $12.20 (8.8% below fair value)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
